Abstract: Heterocyclic compounds and analogues thereof and their use as inhibitors of Mitogen-Activated Protein Kinase-Activated Protein kinase-2 (MAPKAP-k2), and also to a method for preventing or treating a disease or disorder that can be treated or prevented by modulating the activity of MAPKAP-K2 in a subject and to pharmaceutical compositions and kits that include these MAPKAP-K2 inhibitors.
Type:
Application
Filed:
March 19, 2010
Publication date:
July 29, 2010
Applicant:
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Inventors:
Asitha ABEYWARDANE, Craig Andrew MILLER, Tina Marie MORWICK, Neil MOSS, Matthew Russell NETHERTON, Roger John SNOW, Ji WANG, Jiang-Ping WU, Zhaoming XIONG
Abstract: The present invention relates to a material for an organic electro-optical device and an organic electro-optical device including the same. More particularly, the present invention relates to a material having thermal stability of a glass transition temperature of 120° C. or more and a thermal decomposition temperature of 450° C. or more, and being capable of providing an organic electro-optical device having high efficiency and a long life-span due to less crystallization and improved amorphous properties in a material for an organic electro-optical device. The material for an organic electro-optical device can be used singularly or as a host material in combination with a dopant, and includes an asymmetric fluorene derivative compound. An organic electro-optical device including the material for an organic electro-optical device is also provided.
Type:
Application
Filed:
May 28, 2008
Publication date:
July 29, 2010
Applicant:
CHEIL INDUSTRIES INC.
Inventors:
Eun Sun Yu, Nam Soo Kim, Young Hoon Kim, Mi Young Chae
Abstract: The present invention relates to (3-amino-1,2,3,4-tetrahydro-9H-carbazol-9-yl)-acetic acid derivatives of Formula (I) wherein R1, R2, R3, R4, R5 and R6 are as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.
Type:
Application
Filed:
August 2, 2007
Publication date:
July 29, 2010
Applicant:
Actelion Pharmaceuticals Ltd.
Inventors:
Heinz Fretz, Julien Pothier, Philippe Risch
Abstract: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are amide compounds which can be prepared from certain heteroaryl carboxylic acids and certain diazabicycloalkanes. The compounds exhibit selectivity for, and bind with high affinity to, neuronal nicotinic receptors of the ?4?2 subtype in the central nervous system (CNS). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly CNS disorders. The compounds can: (i) alter the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects, and (iii) when employed in effective amounts, not result in appreciable adverse side effects (e.g. side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastrointestinal tract, and significant effects upon skeletal muscle).
Type:
Application
Filed:
March 15, 2010
Publication date:
July 8, 2010
Applicant:
Targacept, Inc.
Inventors:
Anatoly Mazurov, Lan Miao, Yun-De Xiao, Philip S. Hammond, Craig H. Miller, Srinivisa Rao Akireddy, V. Srinivasa Murthy, Regina C. Whitaker, Scott R. Breining, Matt S. Melvin
Abstract: [Problem] To provide a compound which can be used in the prevention and/or treatment of diseases in which 5-HT2B receptor and 5-HT7 receptor are concerned, particularly in the treatment of irritable bowel syndrome (IBS) and/or prevention of migraine. [Means for Resolution] It was found that an acylguanidine derivative having a tricyclic structure or a pharmaceutically acceptable salt thereof has a strong antagonism to 5-HT2B receptor and 5-HT7 receptor. In addition, the compound of the present invention having antagonism to both of the receptors showed superior pharmacological action in comparison with the case of the single use of an antagonist selective for either one of the receptors. Based on the above, the compound of the present invention is useful in preventing and/or treating diseases in which 5-HT2B receptor and 5-HT7 receptor are concerned, particularly in treating irritable bowel syndrome (IBS) and/or preventing migraine.
Abstract: A material for an organic photoelectric device, the material including a compound including a pyridine moiety, the compound being a bipolar organic compound including both a hole transporting unit and an electron transporting unit, the compound being represented by the following Formula 1:
Type:
Application
Filed:
October 13, 2009
Publication date:
June 24, 2010
Inventors:
Eun-Sun Yu, Nam-Soo Kim, Young-Hoon Kim, Mi-Young Chae, Eui-Su Kang
Abstract: Disclosed are an organic electroluminescent device (organic EL device) which is improved in luminous efficiency, fully secured of driving stability, and of simple constitution and a compound useful for the fabrication of said organic EL device. The compound for the organic EL device has an indolocarbazole structure or a structure similar thereto in the molecule wherein an aromatic group is bonded to the nitrogen atom in the indolocarbazole. The organic EL device has a light-emitting layer disposed between an anode and a cathode piled one upon another on a substrate and said light-emitting layer comprises a phosphorescent dopant and the aforementioned compound for an organic electroluminescent device as a host material.
Abstract: Disclosed are a compound for an organic electroluminescent device (organic EL device) which is improved in luminous efficiency, fully secured of driving stability, and of simple constitution and an organic EL device using said compound. The compound for an organic EL device has two indolocarbazole skeletons each of which is bonded to an aromatic group or two skeletons similar thereto. The organic EL device comprises a light-emitting layer disposed between an anode and a cathode piled one upon another on a substrate and said light-emitting layer comprises a phosphorescent dopant and the aforementioned compound for an organic EL device as a host material.
Abstract: The invention relates to heterocyclic derivatives of formula I wherein R, R1, A, B, D, M, L and n are as defined herein, or their physiologically compatible salts, their pharmaceutical compositions and their uses as SCD1 inhibitors.
Type:
Application
Filed:
October 26, 2009
Publication date:
June 10, 2010
Applicant:
SANOFI-AVENTIS
Inventors:
Gerhard ZOLLER, Marc Dietrich VOSS, Stefanie KEIL, Andreas HERLING, Hans MATTER
Abstract: Disclosed are a monomer of iridium complex having a fluoro group as a functional group, a monomer of carbazole derivative having a hydroxy group as the functional group, and a copolymer containing the monomers in its main chain. The iridium complex used as a phosphorescent material and the carbazole derivative having an excellent hole transporting capability are synthesized as the monomer to form the copolymer. The content of iridium complex is easily controlled, and the carbazole derivative and iridium complex are contained in the main chain during the copolymer formation, thereby capable of manufacturing a light emitting device with higher heat resistance and chemical stability.
Type:
Grant
Filed:
November 16, 2007
Date of Patent:
June 1, 2010
Assignee:
Gwangju Institute of Science and Technology
Abstract: The present application relates to calcium channel inhibitors containing compounds of formula (I) wherein L1, L2, R1, R2, and R3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
Type:
Application
Filed:
November 25, 2009
Publication date:
May 27, 2010
Applicant:
ABBOTT LABORATORIES
Inventors:
Andrew O. Stewart, Xenia B. Searle, Daria Darczak, Ming C. Yeung, Stanley DiDomenico, JR.
Abstract: Novel compounds for treatment of cancer and disorders associated with angiogenesis function. Also disclosed are a method of preparing the compounds, pharmaceutical compositions and packaged products containing the compounds, a method of using these molecules to treat cancer (e.g., leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, breast cancer, renal cancer, and prostate cancer) and disorders associated with angiogenesis function (e.g., age-related macular degeneration, macular dystrophy, and diabetes), a method of monitoring the treatment, a method of profiling gene expression, and a method of modulating cell growth, cell cycle, apoptosis, or gene expression.
Abstract: Provided herein are compounds and compositions which comprise the formulae as disclosed herein, wherein the compound is an amyloid binding compound. An amyloid binding compound according to the invention may be administered to a patient in amounts suitable for in vivo imaging of amyloid deposits, and distinguish between neurological tissue with amyloid deposits and normal neurological tissue. Amyloid probes of the invention may be used to detect and quantitate amyloid deposits in diseases including, for example, Down's syndrome, familial Alzheimer's Disease. In another embodiment, the compounds may be used in the treatment or prophylaxis of neurodegenerative disorders. Also provided herein are methods of allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing a neurodegenerative disease.
Type:
Application
Filed:
July 24, 2009
Publication date:
April 22, 2010
Inventors:
Hartmuth C. Kolb, Joseph C. Walsh, Wei Zhang, Umesh B. Gangadharmath, Dhanalakshmi Kasi, Kai Chen, Anjana Sinha, Eric Wang, Gang Chen, Peter J.H. Scott, Henry Clifton Padgett, Qianwa Liang, Zhiyong Gao, Tieming Zhao, Chunfang Xia
Abstract: The present invention relates to 4,5-ring annulated indole derivatives, compositions comprising at least one 4,5-ring annulated indole derivatives, and methods of using the 4,5-ring annulated indole derivatives for treating or preventing a viral infection or a virus-related disorder in a patient. Wherein ring Z, of formula (I), is a cyclopentyl, cyclopentenyl, 5-membered heterocycloalkyl, 5-membered heterocycloalkenyl or 5-membered heteroaryl ring.
Type:
Application
Filed:
December 17, 2007
Publication date:
April 22, 2010
Inventors:
Kevin X. Chen, Srikanth Venkatraman, F. George Njoroge, Stuart B. Rosenblum, Charles A. Lesburg, Jose S. Duca, Neng-Yang Shih, Francisco Velazquez, Gopinadhan N. Anilkumar, Qingbei Zeng, Joseph A. Kozlowski
Abstract: This invention provides 1-substituted-7-azabicyclo[2.2.1]heptyl derivatives, intermediates and methods for producing them, which are therapeutic agents useful for the prevention and treatment of central nervous system disorders and diseases mediated by a Nicotinic Acetylcholine Receptor such as Alzheimer's disease, Parkinson's disease, schizophrenia, epilepsy, pain, nicotine addiction and dementia.
Type:
Application
Filed:
November 4, 2009
Publication date:
April 15, 2010
Applicant:
UNIVERSITEIT GENT
Inventors:
Christian STEVENS, Ann De Blieck, Thomas Heugebaert
Abstract: The present invention discloses novel compounds, which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
Abstract: The present invention relates to novel organic electroluminescent compounds, and organic electroluminescent devices comprising the same as electroluminescent material. Specifically, the organic electroluminescent compounds according to the invention are characterized in that they are represented by Chemical Formula (1): wherein, L1 is a substituent selected from the following structures; A and B independently represent a chemical bond, or a substituent selected from the following structures; m and n independently represent an integer from 0 to 4; provided that, if represents both X1 and X2 represent NR33, and both Y1 and Y2 represent a chemical bond, then R33 does not represent hydrogen or (C1-C5)alkyl. The organic electroluminescent compounds according to the invention exhibit high luminous efficiency in blue color and excellent life property of material, so that an OLED having very good operation life can be prepared therefrom.
Type:
Application
Filed:
June 23, 2009
Publication date:
March 18, 2010
Applicant:
Gracel Display Inc.
Inventors:
Young Jun Cho, Hyuck Joo Kwon, Bong Ok Kim, Sung Min Kim, Seung Soo Yoon
Abstract: The present invention provides a compound of the formula: Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly reduced bones mass, osteoporosis, osteopenia, or reduced muscle mass or strength, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt thereof. X-17142.
Type:
Application
Filed:
November 6, 2007
Publication date:
March 18, 2010
Inventors:
Konstantinos Gavardinas, Jonathan Edward Green, Prabhakar Kondaji Jadhav, Donald Paul Matthews
Abstract: The present invention relates to certain azabicyclic compounds of formula (I)?: wherein the several groups are defined herein and are modulators of dopamine D3 receptors, e.g. to treat drug dependency, as antipsychotic agents, to treat obsessive compulsive spectrum disorders, or premature ejaculation.
Type:
Application
Filed:
March 30, 2007
Publication date:
March 11, 2010
Inventors:
Barbara Bertani, Fabrizio Micheli, Alessandra Pasquarello, Silvia Terreni
Abstract: Novel pyrazole compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)- signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer, and fibrotic diseases.
Abstract: The present application is directed to therapeutic compounds, compositions, and methods for culturing neuronal cells and for preventing and the treatment of neurodegenerative diseases, such as Parkinson's disease and amyotrophic lateral sclerosis (ALS).
Abstract: The invention relates to compounds of the general formula (I): Wherein R, m, n and o are as defined herein. The invention also relates to a method for preparing the same and to the application in therapy.
Abstract: The invention is directed to an amine-based compound represented by Formula 1, an organic light emitting device with an organic film including the same, and a flat panel display device including the organic light emitting device.
Type:
Application
Filed:
July 29, 2009
Publication date:
February 4, 2010
Inventors:
Seok-Hwan Hwang, Yoon-Hyun Kwak, Young-Kook Kim, Jeoung-In Yi, Jong-Hyuk Lee
Abstract: The present invention provides a compound of the formula: Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly frailty, osteoporosis, osteopenia, and male and female sexual dysfunction comprising administering to a patient in need thereof an effective amount of a compound of formula (I).
Type:
Application
Filed:
June 21, 2006
Publication date:
January 28, 2010
Applicant:
CELLECTIS
Inventors:
Kevin Robert Fales, Jonathan Edward Green, Prabhakar Kondaji Jadhav, Donald Paul Matthews, David Andrew Neel, Edward C.R. Smith
Abstract: Compounds of formula I pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals.
Type:
Application
Filed:
August 19, 2009
Publication date:
January 21, 2010
Applicant:
ABBOTT LABORATORIES
Inventors:
Michael R. Schrimpf, Karin R. Tietje, Richard B. Toupence, Jianguo Ji, Anwer Basha, William H. Bunnelle, Jerome F. Daanen, Jennifer M. Frost, Kevin B. Sippy
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.
Type:
Application
Filed:
June 11, 2009
Publication date:
December 31, 2009
Inventors:
Yao-Ling Qiu, Ce Wang, Jiang Long, Lu Ying, Yat Sun Or
Abstract: This invention relates to substituted pyrrolo[3,4-b]pyridinamines having the structural formula IA below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
Type:
Grant
Filed:
May 15, 2008
Date of Patent:
December 8, 2009
Assignees:
AstraZeneca AB, Astex Therapeutics
Inventors:
Gianni Chessari, Miles Stuart Congreve, Jörg Holenz, Christopher Murray, Sahil Patel, Laszlo Rakos, Didier Rotticci
Abstract: This invention relates to novel compounds and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (II-8).
Abstract: Chemokine receptor antagonists, in particular, 3,7-diazabicyclo[3.3.0]octane compounds according to formula (I) wherein R1-R3 and Ar are as defined herein are antagonists of chemokine CCR5 receptors which are useful for treating or preventing an human immunodeficiency virus (HIV) infection, or treating AIDS or ARC. The invention further provides methods for treating diseases that are alleviated with CCR5 antagonists. The invention includes pharmaceutical compositions and methods of using the compounds for the treatment of these diseases. The invention further includes processes for the preparation of compounds according to formula I.
Type:
Grant
Filed:
September 18, 2007
Date of Patent:
December 1, 2009
Assignee:
Roche Palo Alto LLC
Inventors:
Remy Lemoine, Chris Richard Melville, David Mark Rotstein, Jutta Wanner
Abstract: The present application describes selective ligands of formula (I) for neuronal nicotinic receptors (NNRs), more specifically for the ?4?2 NNR subtype, compositions thereof, and methods of using the same, wherein X, R1, X, R2, R3, L1, m, n, p, and q are defined in the specification.
Type:
Application
Filed:
April 27, 2009
Publication date:
November 12, 2009
Applicant:
Abbott Laboratories
Inventors:
William H. Bunnelle, Lei Shi, Marc J.C. Scanio
Abstract: The invention is directed to compounds of Formula (I) useful as delta and mu opioid receptor modulators. Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described.
Type:
Application
Filed:
July 10, 2009
Publication date:
November 5, 2009
Inventors:
Bart DeCorte, Li Liu, Mark McDonnell, Jim McNally
Abstract: The present invention relates to a group of substituted-7-azabicyclo-[2.2.1]heptyl derivatives with biological activity. The present invention also relates to synthetic methods for producing said substituted-7-azabicyclo-[2.2.1]heptyl derivatives. The present invention also relates to certain intermediates for producing such substituted-7-azabicyclo-[2.2.1]heptyl derivatives, as well as a synthetic method for producing such intermediates. The present invention also relates to pharmaceutical compositions comprising such substituted-7-azabicyclo-[2.2.1]heptyl derivatives, as well as their use as medicaments for the treatment of diseases mediated by a Nicotinic Acetylcholine Receptor or a receptor being a member of the Neurotransmitter-gated Ion Channel Superfamily, such as pain, Alzheimer's disease, Parkinson's disease, schizophrenia, epilepsy and nicotine addiction.
Abstract: An optical recording material comprising at least one kind of chalcone type compound represented by the following general formula (I) or a metal complex using the chalcone type compound as a ligand: wherein ring A represents a 5- or 6-membered heterocyclic ring or an aromatic ring; ring B represents a 5- or 6-membered heterocyclic ring, an aromatic ring, or a metallocene structure; the above-mentioned heterocyclic and aromatic ring may be condensed with other rings or may be substituted; n is 0 or 1.
Abstract: The disclosure relates to a compound of formula (I): wherein m, n, Ar, and R are as defined in the disclosure, to compositions containing them and to their therapeutic use. The disclosure also relates to processes for preparing these compounds and to certain intermediate compounds.
Abstract: Compounds of formula I pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals.
Type:
Grant
Filed:
December 15, 2007
Date of Patent:
October 6, 2009
Assignee:
Abbott Laboratories
Inventors:
Michael R. Schrimpf, Karin R. Tietje, Richard B. Toupence, Jianguo Ji, Anwer Basha, William H. Bunnelle, Jerome F. Daanen, Jennifer M. Frost, Kevin B. Sippy
Abstract: A polyimide shown in formula (4) is provided. The polyimide is fabricated by performing a polycondensation reaction with diamine compound shown in formula (2) and various commercial or synthesized dianhydride compounds shown in formula (3) as monomers. In addition, polyimide copolymers are synthesized by various ratios of diamines shown in formulas (2), (7) and (8-1) to (8-7) and a dianhydride compound shown in formula (6). In formulas (3) and (4), Ar represents aromatic groups. In formula (6), X represents aromatic groups or alicyclic groups. In formula (7), n=1 to 10.
Type:
Application
Filed:
March 26, 2009
Publication date:
October 1, 2009
Applicant:
National Taiwan University of Science and Technology
Abstract: An organic compound and a charge-transporting material which are excellent in both a hole-transporting property and an electron-transporting property and have excellent electrical oxidation/reduction durability and a high triplet excitation level are provided, and an organic electroluminescent device which uses this organic compound and has high luminous efficiency and high driving stability and long lifetime is provided.
Abstract: The present invention relates to 1-aza-bicycloalkyl derivatives of formula I, wherein X is CH2 or a single bond; Y is a group of formula and wherein R has the meanings as defined in the specification, which compounds are alpha 7 nicotinic acetylcholine receptor (nAChR) agonists; to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
Abstract: The present invention discloses (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane, salts thereof, and its use to treat pain and other disorders associated with the nicotinic acetylcholine receptor.
Type:
Application
Filed:
April 20, 2009
Publication date:
August 13, 2009
Applicant:
ABBOTT LABORATORIES
Inventors:
Michael J. Buckley, Jianguo Ji, Geoff G.Z. Zhang, Rodger F. Henry, Weili W. Wang, Gregory S. Wayne, Wenke Li, Timothy B. Towne, Steven J. Wittenberger, Steven M. Hannick, Brian J. Kotecki, Bryan S. Macri, Timothy A. Robbins
Abstract: The invention relates biaryl substituted diazabicycloalkanes, and more particularly bicycloheteroaryl substituted fused diazabicycloalkane derivatives, compositions comprising such compounds, and methods of preventing or treating conditions and disorders using such compounds and compositions.
Type:
Application
Filed:
November 20, 2008
Publication date:
August 6, 2009
Applicant:
Abbott Laboratories
Inventors:
Jianguo Ji, Tao Li, Kevin B. Sippy, Chih-Hung Lee, Murali Gopalakrishnan
Abstract: The present invention relates to novel heterocyclic compounds, their analogs, their tautomers, their regioisomers, their stereoisomers, their enantiomers, their diastereomers, their polymorphs, their pharmaceutically acceptable salts, their appropriate N-oxides, their pharmaceutically acceptable solvates and their pharmaceutical compositions containing them. The present invention more particularly relates to novel Phosphodiesterase type 4 (PDE4) inhibitors of the Formula (1), their analogs, tautomers, enantiomers, diasteromers, regioisomers, stereoisomers, polymorphs, pharmaceutically acceptable salts, appropriate N-oxide, pharmaceutically acceptable solvates and the pharmaceutical compositions containing them.
Type:
Application
Filed:
June 2, 2008
Publication date:
July 16, 2009
Applicant:
GLENMARK PHARMACEUTICALS, S.A.
Inventors:
Balasubramanian Gopalan, Laxmikant A. Gharat, Aftab D. Lakdawala, Usha Karunakaran
Abstract: The present invention relates to novel bicyclic enamino(thio)carbonyl compounds, to processes for their preparation and to their use for controlling animal pests, especially arthropods, in particular insects.
Type:
Application
Filed:
March 19, 2007
Publication date:
July 16, 2009
Applicant:
Bayer CropScience AG
Inventors:
Peter Jeschke, Robert Velten, Thomas Schenke, Michael Edmund Beck, Olga Malsam, Udo Reckmann, Ralf Nauen, Ulrich Görgens, Leonardo Pitta, Christian Arnold, Erich Sanwald
Abstract: The present invention relates to novel compounds of the general formula (I), their analogs, their stereoisomers, their polymorphs, their hydrates, their solvates, their pharmaceutically acceptable salts and compositions. The present invention more particularly provides novel compounds of the general formula (I).
Abstract: The present invention relates to compounds according to formula (1) and/or according to formulae (4) to (10) and their use in organic electroluminescent devices, in particular as a matrix material in phosphorescent devices.
Type:
Application
Filed:
May 21, 2007
Publication date:
July 2, 2009
Applicant:
MERCK PATENT GMBH
Inventors:
Ingrid Bach, Arne Buesing, Susanne Heun, Philipp Stoessel, Michael Holbach, Jonas Kroeber, Amir Hossain Parham
Abstract: The invention relates to a group of novel thieno-pyrrole compounds of Formula (I): wherein: R1, R2, R3, R4 and R5 are as defined in the specification, which are useful as gonadotrophin releasing hormone antagonists. The invention also relates to pharmaceutical formulations of said compounds, methods of treatment using said compounds and to processes for the preparation of said compounds.
Type:
Grant
Filed:
May 22, 2007
Date of Patent:
June 16, 2009
Assignee:
AstraZeneca AB
Inventors:
Kevin Michael Foote, Zbigniew Stanley Matusiak, Alexander Graham Dossetter, Jean Claude Arnould, Maryannick Andree Lamorlette, Benedicte Delouvrie, Annie Hamon
Abstract: The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds of formula (I) wherein n, m, p, s, t, R1, R2, A and Z have defined meanings.
Type:
Application
Filed:
March 19, 2007
Publication date:
June 11, 2009
Inventors:
Jean Fernand Armand Lacrampe, Christophe Meyer, Bruno Schoentjes, Delphine Yvonne Raymonde Lardeau, Alain Philippe Poncelet, Luc Van Hijfte
Abstract: Carbazole-containing compounds are provided. In particular, the compounds are oligocarbazole-containing compounds having an unsymmetrical structure. The compounds may be useful in organic light emitting devices, in particular as hosts in the emissive layer of such devices.
Type:
Application
Filed:
November 21, 2008
Publication date:
May 28, 2009
Applicant:
Universal Display Corporation
Inventors:
Chun Lin, Alexey Dyatkin, Zeinab Elshenawy
Abstract: The present invention discloses (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane, salts thereof, and its use to treat pain and other disorders associated with the nicotinic acetylcholine receptor.
Type:
Grant
Filed:
August 14, 2007
Date of Patent:
May 26, 2009
Assignee:
Abbott Laboratories
Inventors:
Michael J. Buckley, Jianguo Ji, Geoff G. Z. Zhang, Rodger F. Henry, Weili W. Wang, Gregory S. Wayne, Wenke Li, Timothy B. Towne, Steven J. Wittenberger, Steven M. Hannick, Brian J. Kotecki, Bryan S. Macri, Timothy A. Robbins